Close Menu

stock rating

Shares of the company climbed as much as 13 percent, and in an analyst note, R.W. Baird said incoming CEO Frank Witney could return Affymetrix to top-line growth.

Macquarie cited competition and potential budget cuts in downgrading Qiagen's shares, lowering its revenue and EPS estimates, and pushing down its target share price.

Analysts revised EPS and revenue estimates as well as target prices following earnings releases on Tuesday by Illumina, Life Technologies, Waters, and Becton Dickinson.

Oppenheimer increased its price target and revenue estimates on Complete Genomics, while Jefferies raised its EPS and price target for Danaher.

An analyst for the investment firm gave PacBio a "Market Perform" rating and Complete Genomics an "Outperform" rating.

Jefferies analyst Jon Wood also raised his price target on the firm's stock to $15.50 from $13, following a presentation by Complete Genomics CEO Clifford Reid at a biotech conference.

The investment firm lowered its estimates from levels predicted last week to reflect lost consumables sales on its older next-gen sequencing platforms and softer microarray consumables sales sequentially.

Analyst Dan Leonard said growth will be driven by what he expects to be record-breaking sales of Illumina's next-generation sequencing platforms, including its HiSeq, in the first and second quarters of 2011.

Macquarie Capital analyst Dane Leone gave Genomic Health an "Outperform" rating and a $34 price target, and Myriad a "Neutral" rating with a $20 share price.

Brian Weinstein expressed concern about competition in the HPV space and a stock that has tracked the overall market since 2007, but gave a thumbs up to the $355 acquisition of Cellestis.

Pages

A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.

Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.

The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.

In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.